Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer: High tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers
Oncology and Translational Medicine · 2025-08 · 11 (4) · 195-197
DOI: 10.1097/ot9.0000000000000089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology and Translational Medicine, online erschienen am 25.06.2025. Verfasst von Cherry Au und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Emerging biomarkers, such as tumor mutational burden and circulating tumor DNA (ctDNA), offer promising tools for identifying patients with prostate cancer who may benefit from immune checkpoint inhibitor therapy. This report describes an exceptional response to pembrolizumab in a patient with a microsatellite stability metastatic castration-resistant prostate cancer and ultrahigh tumor mutational burden. Additionally, this case further emphasizes the utility of ctDNA for monitoring molecular residual disease in patients whose disease burden is not adequately reflected by prostate-specific antigen levels and supports the use of ctDNA as a biomarker for personalized treatment monitoring and guiding treatment de-escalation.
Zitieren
APA
Au, C., Tian, C., Kollipara, R., Vanderweele, D., Christ, T., Kelly, A., & Tan, A. (2025). Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer: High tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers. Oncology and Translational Medicine, 11(4), 195-197. https://doi.org/10.1097/ot9.0000000000000089
Vancouver
Au C, Tian C, Kollipara R, Vanderweele D, Christ T, Kelly A, et al. Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer: High tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers. Oncology and Translational Medicine. 2025;11(4):195-197. doi:10.1097/ot9.0000000000000089
BibTeX
@article{Au2025,
author = {Au, Cherry and Tian, Changtai and Kollipara, Revathi and Vanderweele, David and Christ, Trevor and Kelly, Andrew and Tan, Alan},
title = {Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer: High tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers},
journal = {Oncology and Translational Medicine},
year = {2025},
volume = {11},
number = {4},
pages = {195--197},
doi = {10.1097/ot9.0000000000000089}
}
EUVIMED